Savara Inc (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease, is on track to report top-line data from IMPALA-2 trial this quarter.
IMPALA-2, a Phase III, 48-week placebo-controlled trial, is evaluating the effectiveness of Molgramostim nebulizer solution, a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.